These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 30515670)

  • 1. Restrictive Intraoperative Fluid Therapy is Associated with Decreased Morbidity and Length of Stay Following Hyperthermic Intraperitoneal Chemoperfusion.
    Hendrix RJ; Damle A; Williams C; Harris A; Spanakis S; Lambert DH; Lambert LA
    Ann Surg Oncol; 2019 Feb; 26(2):490-496. PubMed ID: 30515670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Novel Tool for Predicting Major Complications After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy.
    Baumgartner JM; Kwong TG; Ma GL; Messer K; Kelly KJ; Lowy AM
    Ann Surg Oncol; 2016 May; 23(5):1609-17. PubMed ID: 26678406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elevated Maximum Core Body Temperature During Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) is Associated with Increased Postoperative Complications.
    Hendrix RJ; Kassira JP; Lambert LA
    Ann Surg Oncol; 2020 Jan; 27(1):232-239. PubMed ID: 31286314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preoperative Nutrition Status and Postoperative Outcomes in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
    Reece L; Dragicevich H; Lewis C; Rothwell C; Fisher OM; Carey S; Alzahrani NA; Liauw W; Morris DL
    Ann Surg Oncol; 2019 Aug; 26(8):2622-2630. PubMed ID: 31123932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Splenectomy Increases Postoperative Complications Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
    Dagbert F; Thievenaz R; Decullier E; Bakrin N; Cotte E; Rousset P; Vaudoyer D; Passot G; Glehen O
    Ann Surg Oncol; 2016 Jun; 23(6):1980-5. PubMed ID: 26913716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparative analysis of postoperative pancreatic fistulas after surgery with and without hyperthermic intraperitoneal chemoperfusion.
    Downs-Canner S; Ding Y; Magge DR; Jones H; Ramalingam L; Zureikat A; Holtzman M; Ahrendt S; Pingpank J; Zeh HJ; Bartlett DL; Choudry HA
    Ann Surg Oncol; 2015 May; 22(5):1651-7. PubMed ID: 25348781
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enterocutaneous fistula in patients with peritoneal malignancy following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Incidence, management and outcomes.
    Valle SJ; Alzahrani N; Alzahrani S; Traiki TB; Liauw W; Morris DL
    Surg Oncol; 2016 Sep; 25(3):315-20. PubMed ID: 27566038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors Associated with Readmission After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis.
    Martin AS; Abbott DE; Hanseman D; Sussman JE; Kenkel A; Greiwe P; Saeed N; Ahmad SH; Sussman JJ; Ahmad SA
    Ann Surg Oncol; 2016 Jun; 23(6):1941-7. PubMed ID: 26842489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence, Risk Factors, and Prevention Strategies for Venous Thromboembolism after Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
    Khan S; Kelly KJ; Veerapong J; Lowy AM; Baumgartner JM
    Ann Surg Oncol; 2019 Jul; 26(7):2276-2284. PubMed ID: 31065960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extreme cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Outcomes from a single tertiary center.
    Berger Y; Aycart S; Mandeli JP; Heskel M; Sarpel U; Labow DM
    Surg Oncol; 2015 Sep; 24(3):264-9. PubMed ID: 26143715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Repeated cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with recurrent peritoneal carcinomatosis.
    Vassos N; Förtsch T; Aladashvili A; Hohenberger W; Croner RS
    World J Surg Oncol; 2016 Feb; 14(1):42. PubMed ID: 26912149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Morbidity of the abdominal wall resection and reconstruction after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC).
    Nunez MF; Sardi A; Nieroda C; Jimenez W; Sittig M; MacDonald R; Aydin N; Milovanov V; Gushchin V
    Ann Surg Oncol; 2015 May; 22(5):1658-63. PubMed ID: 25245127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perioperative Morbidity of Gastrectomy During CRS-HIPEC: An ACS-NSQIP Analysis.
    Paredes AZ; Guzman-Pruneda FA; Abdel-Misih S; Hays J; Dillhoff ME; Pawlik TM; Cloyd JM
    J Surg Res; 2019 Sep; 241():31-39. PubMed ID: 31004870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of progression in high-grade appendiceal or colorectal peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Baumgartner JM; Tobin L; Heavey SF; Kelly KJ; Roeland EJ; Lowy AM
    Ann Surg Oncol; 2015 May; 22(5):1716-21. PubMed ID: 25145504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Significance of urinary tract involvement in patients treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).
    Votanopoulos KI; Randle RW; Craven B; Swett KR; Levine EA; Shen P; Stewart JH; Mirzazadeh M
    Ann Surg Oncol; 2014 Mar; 21(3):868-74. PubMed ID: 24217789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Repeat Cytoreductive Surgery-Hyperthermic Intraperitoneal Chemoperfusion is Feasible and Offers Survival Benefit in Select Patients with Peritoneal Metastases.
    Choudry HA; Bednar F; Shuai Y; Jones HL; Pai RK; Pingpank JF; Ahrendt SS; Holtzman MP; Zeh HJ; Bartlett DL
    Ann Surg Oncol; 2019 May; 26(5):1445-1453. PubMed ID: 30825033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does Intraoperative Systematic Bacterial Sampling During Complete Cytoreductive Surgery (CRS) with Hyperthermic Intraoperative Peritoneal Chemotherapy (HIPEC) Influence Postoperative Treatment? A New Predictive Factor for Postoperative Abdominal Infectious Complications.
    Dazza M; Schwarz L; Coget J; Frebourg N; Wood G; Huet E; Bridoux V; Veber B; Tuech JJ
    World J Surg; 2016 Dec; 40(12):3035-3043. PubMed ID: 27412631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delayed presentation of major complications in patients undergoing cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy following hospital discharge.
    Bhagwandin SB; Naffouje S; Salti G
    J Surg Oncol; 2015 Mar; 111(3):324-7. PubMed ID: 25557653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyperthermic intraperitoneal chemotherapy plus simultaneous versus staged cytoreductive surgery for gastric cancer with occult peritoneal metastasis.
    Wu X; Li Z; Li Z; Jia Y; Shan F; Ji X; Bu Z; Zhang L; Wu A; Ji J
    J Surg Oncol; 2015 Jun; 111(7):840-7. PubMed ID: 25864884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Comprehensive Complication Index: a New Measure of the Burden of Complications After Hyperthermic Intraperitoneal Chemotherapy.
    Dumitra S; O'Leary M; Raoof M; Wakabayashi M; Dellinger TH; Han ES; Lee SJ; Lee B
    Ann Surg Oncol; 2018 Mar; 25(3):688-693. PubMed ID: 29260417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.